Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04513639 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

StatusRecruiting
PhasePhase 2/3
Started2020-08-27
View on ClinicalTrials.gov ↗

Amendment history

2025-03-17
Study Identification, Study Status v4
Study titlerevised
The Relapse Fromfrom MRD Negativity asAs Indication for Treatment (REMNANT) Study
2022-09-20
Study Status, Contacts/Locations v3
Primary completion date2030-06-01→2031-06-01
Completion date2031-06-01→2032-06-01
Study sitescontacts updated at 1 of 13 sites
2021-06-17
Study Status, Contacts/Locations v2
Study sitesdetails revised at 3 of 13 sites
2021-02-09
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2020-09-01→confirmed 2020-08-27
Study sites4→13
2020-08-12
Original filing
The REMNANT study will evaluate whether treating minimal residual disease (MRD) relapse after first line treatment prolongs progression free survival and overall survival for myeloma patients versus treating relapse after first line treatment at progressive disease. To establish a homogenous group of MRD negative patients after first line treatment including autologous stem cell transplantation, patients are enrolled at diagnosis and treated with Norwegian standard of care first line treatment. MRD negative patients will move on to the randomized part.
Trial Details
NCT Number NCT04513639
Lead Sponsor Oslo University Hospital
Collaborators: St. Olavs Hospital, Haukeland University Hospital, University Hospital of North Norway, University Hospital, Akershus, Helse Stavanger HF, Førde Central Hospital, Sorlandet Hospital HF, Nordlandssykehuset HF, The Hospital of Vestfold, Helse Nord-Trøndelag HF, Alesund Hospital, Sykehuset Ostfold
Conditions Multiple Myeloma
Enrollment 176 participants
Start Date 2020-08-27
Primary Completion 2031-06-01 (estimated)
Study Completion 2032-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-20